Asociatia Oncohelp

Timisoara 15 trials 11 recruiting

15 Registered trials

11 Currently recruiting

Organisation

Asociatia Oncohelp

Location

Timisoara, Romania

Identifier

ORG-100041566

Address

Strada Porumbescu Ciprian 59, 300239, Romania

Departments

Department of Medical Oncology
Gastroenterologie
Gastroenterology
Medical Oncology
n/a
Oncologie medicala
Oncology

Clinical trials at this site (15)

Search interface

Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combination for Inflammatory Bowel Disease Pending

2025-524640-35-00 Ulcerative colitis (Inflammatory Bowel Disease) 4
A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Recruiting

2025-523576-23-00 Unresectable Stage III non-small cell lung cancer witho 5 2026-06-12
A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in … Recruiting

2025-524498-17-00 Pretreated Unresectable Locally Advanced or Metastatic 10 2026-05-08
A phase 2 placebo-controlled trial to investigate visugromab and nivolumab with or without docetaxel in second-line treatment of participant… Recruiting

2024-516794-70-00 Metastatic non-squamous non-small cell lung cancer 4 2025-11-03
Study of GS-1427 in Participants With Moderately to Severely Active UC Recruiting

2023-508304-38-00 Ulcerative Colitis (UC) 4 2024-09-10
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-02) Recruiting

2025-522873-12-00 ER+, HER2- Advanced Breast Cancer 5 2026-02-24
A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg… Recruiting

2025-523083-21-00 PIK3CA-mutant Hormone Receptor Positive, Human Epiderma 5 2025-12-08
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis Recruiting

2025-521242-26-00 Moderately to Severely Active Ulcerative Colitis 4 2025-11-27
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Recruiting

2024-518296-56-00 Crohn’s Disease 5 2025-09-29
Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting

2024-513009-30-00 Moderate to Severe Crohn’s Disease 4 2024-11-21
A Phase 2 Study to Evaluate MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease Recruiting

2023-508158-24-00 Moderately to Severely Active Crohn’s Disease 4 2024-06-25
A Phase 3 study of Dostarlimab as Sequential Therapy after Chemoradiation compared to placebo in adult participants with Locally Advanced Un… Recruiting

2023-508613-17-00 Neoplasms, Head and Neck 5 2024-05-29
A Study to Compare Risankizumab to Vedolizumab in Adult Subjects With Moderate to Severe Ulcerative Colitis Ended

2024-518998-33-00 Ulcerative Colitis 5 2025-07-23
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended

2023-508636-61-00 Crohn’s Disease 5 2024-10-24
Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis Ended

2023-508679-34-00 Ulcerative Colitis 4 2024-07-30